Clinical trial
Enhanced HCV Nonstructural Protein 3 (NS3) -Specific T Cell Proliferation,Interferon γ (IFNγ) and Interleukin-10 (IL-10) Secreting Clones, and Peripheral Blood Natural Killers T Cells ( NKT Cells) in Patients With Type I Gaucher Disease Infected With HCV : An Advantage in Anti Hepatitis Immunity?
NCT01274208 is registered in ClinicalTrials.gov with Shaare Zedek Medical Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Enhanced HCV Nonstructural Protein 3 (NS3) -Specific T Cell Proliferation,Interferon γ (IFNγ) and Interleukin-10 (IL-10) Secreting Clones, and Peripheral Blood Natural Killers T Cells ( NKT Cells) in Patients With Type I Gaucher Disease Infected With HCV : An Advantage in Anti Hepatitis Immunity?
- Lead sponsor
- Shaare Zedek Medical Center
- Phase
- Observational
- Overall status
- Unknown status
- Start date
- January 31, 2011
- Completion date
- April 30, 2016
- Enrollment
- 80 (estimated)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.